Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

NCT06706219 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer (Stage III)

Interventions

DRUG: Sacituzumab tirumotecan plus toripalimab

Sponsor

Hunan Province Tumor Hospital